A randomized, double-blind, placebo-controlled, parallel-design, 5-group, multinational study to evaluate the efficacy, dose response, and safety of tadalafil once-a-day dosing for 12 weeks in men with signs and symptoms of benign prostatic hyperplasia

Trial Profile

A randomized, double-blind, placebo-controlled, parallel-design, 5-group, multinational study to evaluate the efficacy, dose response, and safety of tadalafil once-a-day dosing for 12 weeks in men with signs and symptoms of benign prostatic hyperplasia

Completed
Phase of Trial: Phase II/III

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs Tadalafil (Primary)
  • Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
  • Focus Therapeutic Use
  • Sponsors Eli Lilly; Lilly ICOS
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Apr 2016 Results of a pooled analysis from four trials (n= 1462) published in the Journal of Urology
    • 24 Aug 2015 Results of post-hoc analysis of pooled data from four trials published in the International Journal of Clinical Practice.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top